FDA Clears Gold Standard Diagnostics Lyme Assay

FDA has cleared a Gold Standard Diagnostics 510(k) for its Borrelia burgdorferi IgG/IgM ELISA assay. The test is intended as an initial screening assay in the CDC-recommended two-step testing for evidence of antibodies against the Lyme disease bacteria. Both steps can be performed using the same blood sample, according to the company. It screens for B. burgdorferi strains B31 and 2591, as well as VIsE, an immunogenic lipoprotein, it says.

Read more